At 7.2% CAGR, Europe Gastrointestinal Drugs Market is Projected to be Worth US$ 34,299.35 Million by 2031, Says Business Market Insights

According to Business Market Insights' research, the Europe gastrointestinal drugs market was valued at US$ 19,650.29 in 2023 and is expected to reach US$ 34,299.35 million by 2031, registering a CAGR of 7.2% from 2023 to 2031. Increasing development of biologics and rising cases of gastrointestinal diseases are among the critical factors attributed to the Europe gastrointestinal drugs market expansion.

In the past few years, there has been a rise in the development of advanced new treatments such as biologics, which are utilized for the treatment of inflammatory diseases. In addition, biologics have transformed the IBD treatment, and their success in the treatment of these conditions is supporting the use of biologics in other gastrointestinal conditions. Biologics are also effective in treating eosinophilic esophagitis, celiac disease, autoimmune hepatitis, and other gastrointestinal diseases because they target the disease-causing elements in the immune system. Many ulcerative colitis medications have wide-ranging effects on the immune system. To block such effects of the inflammatory process, biologics are widely used. One such group of biologic drugs for ulcerative colitis is known as anti-TNF drugs that block a protein called tumor necrosis factor-alpha (TNF alpha). This protein promotes inflammation in the intestines and specific other organs. Anti-TNF agents were the first class of biologics to be authorized for IBD treatment, and since then, they have tremendously changed IBD management. A few types of anti-TNF drugs include Humira, Simponi, and Remicade. A variety of biological drugs can reduce IBD symptoms in adults and help achieve remission. Biologic medications can be an effective substitute to help control the symptoms of ulcerative colitis. The FDA has approved many biologic drugs such as Humira (adalimumab), Cimzia, Simponi (golimumab), Tysabri, Remicade (infliximab), Entyvio (Vedolizumab), and Stelara (ustekinumab) for the treatment of Crohn’s disease and ulcerative colitis.

Many companies are involved in developing a wide range of biologic drugs. In July 2020, Takeda Pharmaceutical launched the biologic drug—Vedolizumab—as part of its gastrointestinal portfolio in India. Vedolizumab is sold in the country under the brand name Kynteles. It is used to treat a variety of chronic IBD. Vedolizumab has become the first choice among second-line biologics for the treatment of moderate to severe Crohn's disease and ulcerative colitis patients who have experienced failure with conventional medications or anti-TNF agents. Similarly, Celltrion Healthcare received marketing authorization approval from the European Commission for Remsima (infliximab, CT-P13) in July 2020. It is a subcutaneous formulation for the treatment of patients suffering from Crohn’s disease and ulcerative colitis. Thus, the increasing development of biologics for the treatment of gastrointestinal diseases drives the gastrointestinal drugs market.

On the contrary, high cost of biologics hampers the growth of Europe gastrointestinal drugs market.

Based on drug class, the Europe gastrointestinal drugs market is segmented into biologics, antidiarrheal and laxatives, acid neutralizers, anti-inflammatory drugs, antiemetic and antinauseants and others. The biologics segment held 27.4% share of the Europe gastrointestinal drugs market in 2023, amassing US$ 5,393.36 million. It is projected to garner US$ 9,513.31 million by 2031 to expand at 7.4% CAGR during 2023–2031.

By application, the Europe gastrointestinal drugs market is segmented into irritable bowel syndrome, inflammatory ulcerative colitis, Crohn’s disease, gastroenteritis, celiac disease and others. The irritable bowel syndrome segment held 30.6% share of the Europe gastrointestinal drugs market in 2023, amassing US$ 6,013.44 million. It is projected to garner US$ 10,779.22 million by 2031 to expand at 7.6% CAGR during 2023–2031.

By route of administration, the Europe gastrointestinal drugs market is bifurcated into oral and parenteral. The oral segment held 67.3% share of the Europe gastrointestinal drugs market in 2023, amassing US$ 13,216.58 million. It is projected to garner US$ 23,882.17 million by 2031 to expand at 7.7% CAGR during 2023–2031.

By distribution channel, the Europe gastrointestinal drugs market is segmented into hospital pharmacies, retail pharmacies, and online pharmacies. The hospital pharmacies segment held 46.3% share of the Europe gastrointestinal drugs market in 2023, amassing US$ 9,089.31 million. It is projected to garner US$ 16,550.00 million by 2031 to expand at 7.8% CAGR during 2023–2031.

Based on country, the Europe gastrointestinal drugs market is segmented into Germany, the UK, France, Italy, Spain, and the Rest of Europe. Germany held 28.8% share of Europe gastrointestinal drugs market in 2023, amassing US$ 5,651.93 million. It is projected to garner US$ 10,164.84 million by 2031 to expand at 7.6% CAGR during 2023–2031.

Key players operating in the Europe gastrointestinal drugs market are Sanofi SA, GSK Plc, Johnson & Johnson, Bausch Health Companies Inc, AstraZeneca Plc, Takeda Pharmaceutical Co Ltd, AbbVie Inc, Bayer AG, and Pfizer Inc, among others.

Contact Us
Phone: +16467917070
Email Id: sales@businessmarketinsights.com